Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $4,701,051.96 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sold 434,478 shares of the firm’s stock in a transaction on Monday, March 24th. The stock was sold at an average price of $10.82, for a total value of $4,701,051.96. Following the transaction, the chief operating officer now directly owns 1,127,290 shares of the company’s stock, valued at approximately $12,197,277.80. This represents a 27.82 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Eric Venker also recently made the following trade(s):

• On Thursday, March 20th, Eric Venker sold 315,522 shares of Roivant Sciences stock. The shares were sold at an average price of $11.06, for a total value of $3,489,673.32.
• On Thursday, February 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $10.65, for a total value of $1,065,000.00.
• On Thursday, February 13th, Eric Venker sold 218,041 shares of Roivant Sciences stock. The shares were sold at an average price of $10.42, for a total transaction of $2,271,987.22.
• On Tuesday, January 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.28, for a total transaction of $1,128,000.00.
• On Monday, December 30th, Eric Venker sold 177,704 shares of Roivant Sciences stock. The stock was sold at an average price of $11.54, for a total transaction of $2,050,704.16.
• On Friday, December 27th, Eric Venker sold 176,900 shares of Roivant Sciences stock. The shares were sold at an average price of $11.82, for a total transaction of $2,090,958.00.

Roivant Sciences Price Performance

Shares of ROIV stock traded up $0.04 on Monday, reaching $10.83. 6,976,198 shares of the company were exchanged, compared to its average volume of 5,636,264. The company has a 50-day moving average of $10.78 and a 200-day moving average of $11.46. The company has a market cap of $7.73 billion, a price-to-earnings ratio of -72.20 and a beta of 1.26. Roivant Sciences Ltd. has a one year low of $9.93 and a one year high of $13.06.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings results on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. As a group, sell-side analysts predict that Roivant Sciences Ltd. will post -0.92 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on ROIV shares. HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of Roivant Sciences in a research report on Tuesday, February 11th. Cantor Fitzgerald upgraded Roivant Sciences to a “strong-buy” rating in a report on Tuesday, March 4th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Roivant Sciences currently has a consensus rating of “Buy” and a consensus price target of $18.08.

Institutional Trading of Roivant Sciences

Several hedge funds have recently bought and sold shares of the business. Norges Bank bought a new position in shares of Roivant Sciences in the fourth quarter valued at $52,443,000. TOMS Capital Investment Management LP acquired a new stake in shares of Roivant Sciences in the 3rd quarter worth about $46,333,000. Invesco Ltd. raised its holdings in shares of Roivant Sciences by 49.7% in the 4th quarter. Invesco Ltd. now owns 9,515,058 shares of the company’s stock worth $112,563,000 after acquiring an additional 3,159,603 shares during the last quarter. FMR LLC lifted its position in Roivant Sciences by 5.6% in the 3rd quarter. FMR LLC now owns 49,145,056 shares of the company’s stock valued at $567,134,000 after acquiring an additional 2,593,910 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in Roivant Sciences by 5.8% during the 4th quarter. Vanguard Group Inc. now owns 44,087,287 shares of the company’s stock valued at $521,553,000 after purchasing an additional 2,404,232 shares during the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.